beraprost and Leukemia--Erythroblastic--Acute

beraprost has been researched along with Leukemia--Erythroblastic--Acute* in 1 studies

Other Studies

1 other study(ies) available for beraprost and Leukemia--Erythroblastic--Acute

Article	Year
The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells. Prostaglandins & other lipid mediators, 2007, Volume: 83, Issue:3 Phorbol-12-myristate-13-acetate (PMA) induces megakaryocytopoeisis in human erythroleukemia (HEL) cells which is characterized by the increase in cell size, increase in nuclear polyploidization and expression of megakaryocyte marker, CD41. However, upon treatment with 100 nM of selective prostacyclin (IP) agonist beraprost inhibits the induced differentiation. Moreover, selective non-prostanoid IP agonist, BMY 45778 prevents PMA induced megakaryocytopoeisis in HEL cells similarly, while prostaglandin E(2) and specific EP(3) agonist sulprostone have no effect. Thus, IP receptor is involved. Furthermore, adenylate cyclase activator forskolin and cAMP analog dibutyryl-cAMP also prevented PMA induced megakaryocytopoeisis in HEL cells. Thus, IP agonists inhibition of PMA induced megakaryocytopoeisis in HEL cells may involve a cAMP dependent pathway. Topics: Acetates; Cell Differentiation; Epoprostenol; Humans; Leukemia, Erythroblastic, Acute; Oxazoles; Phorbol Esters; Thrombopoiesis	2007

Article

Year

The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells.

Prostaglandins & other lipid mediators, 2007, Volume: 83, Issue:3

Phorbol-12-myristate-13-acetate (PMA) induces megakaryocytopoeisis in human erythroleukemia (HEL) cells which is characterized by the increase in cell size, increase in nuclear polyploidization and expression of megakaryocyte marker, CD41. However, upon treatment with 100 nM of selective prostacyclin (IP) agonist beraprost inhibits the induced differentiation. Moreover, selective non-prostanoid IP agonist, BMY 45778 prevents PMA induced megakaryocytopoeisis in HEL cells similarly, while prostaglandin E(2) and specific EP(3) agonist sulprostone have no effect. Thus, IP receptor is involved. Furthermore, adenylate cyclase activator forskolin and cAMP analog dibutyryl-cAMP also prevented PMA induced megakaryocytopoeisis in HEL cells. Thus, IP agonists inhibition of PMA induced megakaryocytopoeisis in HEL cells may involve a cAMP dependent pathway.

Topics: Acetates; Cell Differentiation; Epoprostenol; Humans; Leukemia, Erythroblastic, Acute; Oxazoles; Phorbol Esters; Thrombopoiesis

2007